Supplementary Table 2. Changes in the continuous glucose monitoring variables from baseline to week 12 in patients with glycosylated hemoglobin <7.5%

Parameter	Teneligliptin (n=21)	Placebo (n=18)	Between-group difference (95% CI)	P value[c]
Mean glucose, mg/dL				
Baseline[a]	160.2±19.7	167.0±18.9		
Change from baseline[b]	−21.5±5.1	−2.7±5.4	−18.9 (−33.2 to −4.6)	0.011
CV, %				
Baseline[a]	26.9±6.7	26.3±5.1		
Change from baseline[b]	−5.5±1.3	−0.9±1.4	−4.7 (−8.1 to −1.2)	0.009
SD, mg/dL				
Baseline[a]	43.1±11.9	43.8±9.0		
Change from baseline[b]	−12.7±2.5	−0.6±2.7	−12.1 (−19.3 to −4.9)	0.002
MAGE, mg/dL				
Baseline[a]	107.7±31.1	108.8±25.5		
Change from baseline[b]	−34.2±6.5	−7.4±7.1	−26.8 (−44.1 to −9.6)	0.003
TIR70–180 mg/dL, %				
Baseline[a]	69.6±15.4	64.1±16.0		
Change from baseline[b]	18.4±3.5	5.3±3.7	13.1 (3.3 to 22.9)	0.010
TAR>250 mg/dL, %				
Baseline[a]	5.0±5.2	6.0±4.6		
Change from baseline[b]	−4.4±1.9	1.5±2.0	−5.9 (−11.1 to −0.6)	0.031
TAR>180 mg/dL, %				
Baseline[a]	26.8±14.2	32.9±15.4		
Change from baseline[b]	−16.6±3.3	−5.4±3.4	−11.2 (−20.3 to −2.1)	0.018
TBR<70 mg/dL, %				
Baseline[a]	0.4±1.1	0.1±0.3		
Change from baseline[b]	−0.1±0.2	−0.1±0.2	−0.0 (−0.7 to 0.6)	0.870
TBR<54 mg/dL, %				
Baseline[a]	0.1±0.4	0.0±0.1		
Change from baseline[b]	−0.1±0.1	0.0±0.1	−0.1 (−0.5 to 0.2)	0.373

Values are presented as mean±standard deviation or least squares mean±standard error.

CI, confidence interval; CV, coefficient of variation; SD, standard deviation; MAGE, mean amplitude of glycemic excursion; TIR, time in target glucose range; TAR, time above target glucose range; TBR, time below target glucose range.

[a]Wilcoxon rank-sum test, [b]Least squares mean±standard error, [c]Analysis of covariance (ANCOVA) with baseline values and stratification factors (at randomization) as covariates.